FDA label and CMS Medicare guidance checked Oct 2026
Wegovy for Heart Risk: What the SELECT Approval Covers
Since Mar 8, 2024, Wegovy is FDA-approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight. In the SELECT trial it cut those events by 20%.
- FDA-approved for this use
- No diabetes required
- Medicare Part D can cover it
- Not a heart failure treatment
We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
Chia Health
Our #1 pick for GLP-1 weight loss online
- One monthly price: clinician, medication and free shipping included
- Semaglutide or tirzepatide, as a weekly injection or a daily tablet
- No insurance needed; HSA/FSA and Klarna accepted
Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure
$212.89 first month, then $349/mo
6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.
01 The approval
What the FDA Approved for Wegovy and the Heart
On March 8, 2024, the FDA approved Wegovy (semaglutide) injection "to reduce the risk of major adverse cardiovascular events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight." The FDA called it the first treatment approved to reduce the risk of serious heart problems specifically in adults with obesity or overweight. The Wegovy pill gained the same indication with its own approval on December 22, 2025.
pen; pill Dec 22, 2025
plus obesity or overweight
1.7 mg if 2.4 mg is not tolerated
7.2 mg is weight-only
"Established CV disease" in the trial meant a prior heart attack, a prior stroke or peripheral artery disease. Obesity means a BMI of 30 or more, overweight 27 to 29.9; check yours with our BMI calculator. The dose climbs over 16 weeks from 0.25 mg, the same schedule as for weight loss; see Wegovy dosage.
02 Trial results
SELECT Trial Results, Event by Event
SELECT randomized 17,604 adults aged 45 or older to Wegovy 2.4 mg or placebo on top of standard heart care: 90% took a cholesterol drug and 86% an antiplatelet drug. Median follow-up was 41.8 months. Only the first row was the primary endpoint; the others are context, and the label is careful about which ones were proven.
| Event | Placebo | Wegovy | Hazard ratio (95% CI) | Label note |
|---|---|---|---|---|
| Heart attack, stroke or CV death (primary) HR 0.80 (0.72 to 0.90) · Significant | 8.0% | 6.5% | 0.80 (0.72 to 0.90) | Significant |
| Heart attack, fatal or not HR 0.72 (0.61 to 0.85) · Not in testing hierarchy | 3.8% | 2.8% | 0.72 (0.61 to 0.85) | Not in testing hierarchy |
| Stroke, fatal or not HR 0.89 (0.72 to 1.11) · Not in testing hierarchy | 2.0% | 1.8% | 0.89 (0.72 to 1.11) | Not in testing hierarchy |
| Cardiovascular death HR 0.85 (0.71 to 1.01) · Superiority not confirmed | 3.0% | 2.5% | 0.85 (0.71 to 1.01) | Superiority not confirmed |
| Death from any cause HR 0.81 (0.71 to 0.93) · Not significant in hierarchy | 5.2% | 4.3% | 0.81 (0.71 to 0.93) | Not significant in hierarchy |
| Heart failure hospitalization or urgent visit HR 0.79 (0.60 to 1.03) · Effect not established | 1.4% | 1.1% | 0.79 (0.60 to 1.03) | Effect not established |
Share of patients with at least one event. Source: Wegovy prescribing information, section 14.1, Table 6, revised 06/2026.
Heart attack, stroke or cardiovascular death
- Placebo8.0%
- Wegovy 2.4 mg6.5%
At week 104, weight was down 9.4% on Wegovy versus 0.9% on placebo, and systolic blood pressure fell 3.8 versus 0.5 mmHg (label Table 7). The label adds that the benefit held regardless of age, sex, race, starting BMI or kidney function. Heart rate rose by about 3 beats a minute versus placebo.
03 Eligibility
Who Qualifies for Wegovy to Lower Heart Risk
- 1
Adult with established cardiovascular disease. In SELECT: a prior heart attack (76% of patients), prior stroke (23%) or peripheral artery disease (9%).
- 2
BMI of 27 or higher. The trial's average BMI was 33.
- 3
Usually no type 2 diabetes. SELECT excluded diabetes. If you have it, Ozempic already carries a heart-risk approval for type 2 diabetes with heart disease, and your prescriber weighs both.
- 4
Staying on your heart medicines. Wegovy is added to statins, blood thinners and blood pressure drugs, not swapped for them. Some insurers require that you take them.
- 5
No medullary thyroid cancer or MEN 2 in you or your family; these are label contraindications.
04 Insurance
Wegovy Heart Risk Insurance: Separate Criteria From Weight Loss
Many commercial plans that exclude weight-loss drugs review Wegovy for heart risk under a separate policy. Ask the plan for "Wegovy for cardiovascular risk reduction" by name.
UnitedHealthcare
Covered with prior authorization even on plans that exclude weight loss: age 45+, BMI 27+, prior heart attack, stroke or symptomatic PAD, and on standard heart medicines (policy P 1445-4, May 1, 2026). Details.
CVS Caremark / Aetna
Heart-risk requests have their own criteria in the 5098-C policy; Wegovy HD is not included. Details.
Blue Cross plans
Blue Cross VT still covers Wegovy for heart disease with obesity despite a weight-loss exclusion; BCBS of South Carolina may cover it for heart risk with PA from Aug 1, 2026. Details.
If approved on a commercial plan, the Wegovy savings card can bring a fill to as little as $25 (maximum savings $100 a month). If denied: appeal, or self-pay at $349/mo for the pen. More in Wegovy insurance and Wegovy cost.
05 Medicare
Medicare for Wegovy Heart Risk: Part D, Not the Bridge
Heart risk is the use that first opened Medicare to Wegovy: in March 2024 CMS confirmed that an obesity drug approved for another medically accepted use can be a Part D drug for that use. CMS now says a prescription written "in order to" reduce heart attack and stroke risk goes to your Part D plan. Having heart disease does not bar you from the Bridge if the drug is prescribed for weight management.
| Topic | Part D plan (heart risk) | GLP-1 Bridge (weight) |
|---|---|---|
| Prescribed to | Lower heart attack, stroke and CV death risk | Manage weight |
| Who | Established heart disease plus BMI 27+ | BMI 35 or higher; or BMI 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension or chronic kidney disease stage 3a or higher; or BMI 27 or higher with prediabetes, a prior heart attack, a prior stroke or symptomatic peripheral artery disease |
| You pay | Your plan's copay or coinsurance | $50/mo |
| Dates | Ongoing | Jul 1, 2026 to Dec 31, 2027 |
| Savings card | Not allowed | Not allowed |
Sources: CMS Bridge information for Part D plans; KFF, March 2024. Full rules: Medicare GLP-1 Bridge and Medicare coverage.
On Medicare and want a clinician to sort out which route fits you? Telehealth primary care can write the prescription and paperwork.
See a clinician through Amazon One Medical06 Cost
Wegovy Price for Heart Risk Without Insurance
$199 for the first 2 fills
by dose
per 4-pen box
$199/mo for the first 2 fills at 0.25 and 0.5 mg (new NovoCare patients, through Dec 31, 2026), then $349/mo for 0.25–2.4 mg. Wegovy HD 7.2 mg $399/mo. Source: NovoCare, Oct 2026. Compare pen and pill: Wegovy pill vs injection.
07 FAQ
Wegovy Heart Risk FAQ
Is Wegovy approved for heart disease?
How much does Wegovy lower heart attack and stroke risk?
Do I need diabetes to get Wegovy for heart risk?
Does Medicare cover Wegovy for heart disease?
Is the Wegovy pill approved for heart risk too?
How much is Wegovy for heart risk without insurance?
Other approved uses: what GLP-1 is used for · Wegovy for MASH · Ozempic for kidney disease.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Last updated Oct 29, 2026 · trial figures from the Wegovy label (06/2026) · Medicare rules from CMS · prices from NovoCare, Oct 2026.
References
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight, Mar 8, 2024, checked 2026-10-23, U.S. Food and Drug Administration, 2024
- Wegovy (semaglutide) Prescribing Information, revised 06/2026, sections 1, 2.2, 14.1 (Tables 6 and 7), checked 2026-10-23, Novo Nordisk / FDA, 2026
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232, New England Journal of Medicine, 2023
- Medicare GLP-1 Bridge: information for Part D plans, checked 2026-10-23, Centers for Medicare & Medicaid Services, 2026
- A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity, KFF, 2024
- Prior Authorization/Non-Formulary: Wegovy, Cardiovascular Risk Reduction and MASH Only, 2026 P 1445-4, effective May 1, 2026, UnitedHealthcare Pharmacy, 2026
- Wegovy self-pay and savings offer, checked 2026-10-16, NovoCare, 2026